August 10, 2026

Connecting Structure and Function in GA

Post hoc GATHER2 analyses suggest ellipsoid zone integrity and low-luminance deficit may provide complementary measures of disease progression and treatment response.

July 23, 2026

Recognizing the Best of JVRD in 2026

Journal of VitreoRetinal Diseases Editor-in-Chief Timothy G. Murray, MD, MBA, FASRS, reviews this year's most influential articles and discusses the journal’s next chapter as it transitions to a self-publishing model.

July 23, 2026

Real-World Study Finds Similar Rates of GA Lesion Growth During Treatment With Izervay or Syfovre

Josh O. Wallsh, MD, presented a same-eye comparison of avacincaptad pegol and pegcetacoplan at ASRS 2026, finding no statistically significant difference in geographic atrophy lesion growth rates.

July 23, 2026

Evaluating Complement Inhibition Across GA Populations

An AI-assisted real-world analysis found reduced RPE and photoreceptor loss after pegcetacoplan treatment in patients with GA, including those with concomitant neovascular AMD.

July 23, 2026

K8 Delivers Encouraging Phase 2 Results

A sustained-release inflammasome inhibitor reduced lesion growth while demonstrating a statistically significant BCVA benefit in patients with geographic atrophy.

July 22, 2026

Could Gene Therapy Change Retina Care for Rural Veterans?

Drawing on his experience caring for veterans in northern California, Frank Brodie, MD, MBA, explains why gene therapy may be particularly meaningful for patients who travel long distances for routine anti-VEGF treatment.

July 22, 2026

What Imaging Reveals About OCU410

At ASRS 2026, Jay Chhablani, MD, reviews quantitative imaging analyses showing reduced structural progression with gene therapy OCU410, along with a favorable safety profile.

July 22, 2026

5 Years of Gene Therapy: What the OPTIC Data Show

Szilárd Kiss, MD, FASRS, reviews 5-year findings from the OPTIC program in neovascular AMD patients with high anti-VEGF treatment needs, showing stable vision, substantially reduced treatment burden, and a favorable long-term safety profile.

July 21, 2026

Drs. Berrocal Reflect on ASRS 2026

ASRS 2026 meeting program chair Audina M. “Nina” Berrocal, MD, FASRS, joins Maria H. Berrocal, MD, to discuss the meeting’s highlights, surgical sessions, and educational approach.

July 21, 2026

What Retina Specialists Have Learned From TRUCKEE

Carl J. Danzig, MD, reviews 4.5 years of real-world findings showing sustained anatomic improvements, longer treatment intervals, and a favorable safety profile with faricimab in neovascular AMD.

July 21, 2026

Treating CME Without Reactivating Retinitis

Data from a retrospective Emory Eye Center series suggest most eyes with CME following infectious retinitis achieved resolution without disease reactivation, although prolonged treatment and close monitoring were often required.

July 20, 2026

ORG Detects Retinal Dysfunction Before Structural Changes

At ASRS 2026, Kareem Moussa, MD, presented early data suggesting optoretinography may identify photoreceptor dysfunction in diabetic eyes before conventional imaging reveals abnormalities.

July 20, 2026

OTX-TKI: Inside the SOL-1 Data

At ASRS 2026, Dilsher S. Dhoot, MD, FASRS, shared additional phase 3 SOL-1 data on vision maintenance, rescue treatment, and safety with investigational OTX-TKI (Axpaxli) in neovascular AMD.

July 20, 2026

The New Rules of Retina Drug Development

In a panel discussion at the Retina Innovation Summit in Montreal, regulatory experts, drug developers, academic advisors, and investors discussed how evolving FDA guidance is reshaping the path from clinical trials to approval.

July 20, 2026

The Promise of Gene Therapy

With phase 3 topline data for sura-vec expected later this year, Arshad M. Khanani, MD, FASRS, reflects on how gene therapy could transform long-term treatment for nAMD.

July 20, 2026

Can Stem Cell Therapy Slow GA?

Phase 1b data for ASP7317, presented at ASRS, showed a favorable safety profile, encouraging visual acuity findings, and stabilization of geographic atrophy in patients with advanced disease.

July 20, 2026

OLN324: Why Size May Matter

David A. Eichenbaum, MD, FASRS, and Veeral S. Sheth, MD, MBA, discuss phase 1 JADE findings and how OLN324's small-format design may contribute to improved retinal drying in nAMD and diabetic macular edema.

July 20, 2026

Expanding Optogenetics to Geographic Atrophy

Jordi Monés, MD, PhD, discusses the rationale for evaluating MCO-010 in GA following encouraging findings in retinitis pigmentosa and Stargardt disease.

July 19, 2026

The Economics of Home OCT

At ASRS 2026, Sean Berkowitz, MD, MBA, examined the payer costs and physician workload associated with home OCT monitoring for wet AMD.

July 19, 2026

ASRS President Reflects on a Year of Change

As his term comes to a close, Geoffrey G. Emerson, MD, PhD, FASRS, discusses scientific advances, physician advocacy, and the collaborative leadership behind ASRS.

July 19, 2026

Lessons From the ARCHER Trial

Margaret A. Chang, MD, MS, discusses how findings from the phase 2 ARCHER trial informed the design of the ongoing phase 3 ARCHER II study of vonaprument, which is expected to read out later this year.

July 19, 2026

Merck Highlights Early Tiespectus Data

At the ASRS meeting in Montreal, Baruch D. Kuppermann, MD, PhD, presented BRVO findings from the phase 1/2a RIOJA program evaluating the investigational VEGF/Tie2 bispecific.

July 19, 2026

Does Timing Matter in Gene Therapy for nAMD?

Carl C. Awh, MD, FASRS, discusses 2-year phase 2b PRISM results showing durable outcomes with investigational 4D-150 in patients with recently diagnosed neovascular age-related macular degeneration.

July 19, 2026

A First Look at Phase 2 ArMaDa Data

Arshad M. Khanani, MD, FASRS, discusses phase 2 findings for OCU410, an investigational gene therapy for geographic atrophy. A phase 3 program is expected to begin later this year.

July 17, 2026

Stuart Therapeutics Spotlights Topical RP Program

At OIS Retina, Eric Schlumpf discussed the company’s collagen mimetic peptide platform for retinitis pigmentosa, now in preclinical development.

July 17, 2026

Alkeus Launches Phase 3 Stargardt Trial

At OIS Retina, Carlos Quezada Ruiz, MD, highlighted the launch of the global phase 3 NORTHSTAR trial evaluating oral gildeuretinol for Stargardt disease.

July 17, 2026

Neuroprotection: Retina's Next Frontier?

At OIS Retina in Montreal, Riad Sherif, MD, discussed Oculis’s optic neuritis program and why neuroprotection may represent the next frontier in retinal therapeutics.

July 16, 2026

CMS Proposal Would Cut Payment for Same-Day Injection Visits

The proposed Physician Fee Schedule for 2027 includes changes affecting intravitreal injections, E/M services, and physician payment.